Dfe Pharma India Profile
Key Indicators
- Authorised Capital ₹ 61.12 Cr
- Paid Up Capital ₹ 61.12 Cr
- Company Age 5 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
About Dfe Pharma India
Dfe Pharma India Private Limited (DPIPL) is a Private Limited Foreign Company Incorporated In India incorporated in India on 15 May 2019 (Five years and nine months 12 days old ). Its registered office is in Cuddalore, Tamil Nadu, India.
The Company is engaged in the Business Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 61.12 Cr and a paid-up capital of Rs 61.12 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Dfe Pharma India Private Limited India is Nikita Khandelwal as COMPANY SECRETARY. Preetam Shetty, Aditya Chitharanjan, Jayaprabbu Subbaraj, and One other member serve as directors at the Company.
Company Details
- Location
Cuddalore, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24299TN2019FTC129309
- Company No.
129309
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
15 May 2019
- Date of AGM
29 Dec 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Dfe Pharma India?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Nikita Khandelwal | Company Secretary | 20-Mar-2020 | Current |
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Martti Hedman  | Director | 26-Apr-2022 | Current |
Preetam Shetty  | Director | 01-Apr-2022 | Current |
| Aditya Chitharanjan | Director | 01-Jan-2021 | Current |
| Jayaprabbu Subbaraj | Director | 01-Nov-2019 | Current |
Financial Performance of Dfe Pharma India.
Dfe Pharma India Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Dfe Pharma India?
In 2023, Dfe Pharma India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Chith Warehouse Private LimitedAditya Chitharanjan is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dfe Pharma India?
Dfe Pharma India has a workforce of 134 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dfe Pharma India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dfe Pharma India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
